The goals of the Sloan Kettering Institute’s Molecular Pharmacology Program include the conception, design, and synthesis of new anticancer, neurological, and antiviral agents; elucidation of mechanisms of action and resistance of anticancer agents; preclinical evaluation and toxicology of promising new agents; translational research bearing on radiation, molecular imaging, and chemotherapy; strategic design of new therapies; and broader aspects of cancer etiology, and pathogenesis.
The program functions as a conduit for bringing discoveries in the basic biological sciences – generated from cancer-related molecular pharmacology and from the other research programs - to preclinical and clinical evaluation. More than half of our researchers are engaged in laboratory-associated clinical investigation.
The Molecular Pharmacology Program includes faculty immersed in the whole spectrum of pharmacological fields, ranging from small molecule drug development, drug sensitivity and resistance, molecular biology of drug action, cell signaling, drug delivery, transcriptional regulation, stem cells, neuropharmacology, as well as antibody, cell, vaccine, and cytokine therapies, nanoparticle design and applications, smart drugs and imaging agents.
Discoveries from the laboratory are often tested in clinic at Memorial Hospital. New treatment strategies for patients, based on a mechanistic understanding of cancer causation, or tumor phenotyping and genotyping, are constantly in development.